Featured past event: ASTMH Symposium - Severe Malaria: improving the continuum of care
Find out more
The Severe Malaria Observatory: Experience. Evidence. Guidance.
Click here to see what you missed in our last newsletter. To receive upcoming newsletters, please subscribe.
La présente étude a été réalisée pour identifier les obstacles et les opportunités rencontrés dans la prise en charge du paludisme grave afin de réduire la mortalité associée à cette maladie en RDC.
The Severe Malaria Observatory is pleased to announce the launch of its French website. This website will be a welcome addition which will assist the malaria community and communities impacted by malaria in French speaking countries to access information on severe malaria prevention, treatment as well as national and international policies and guidance. The French website can be found at www.severemalaria.org/fr
When severe malaria is suspected in children, WHO recommends pre-treatment with a single rectal dose of artesunate before referral to an appropriate facility. This was an individually randomized, open-label, 2-arm, cross-over clinical trial in 83 Congolese children with severe falciparum malaria, to characterize the pharmacokinetics of rectal artesunate. At admission, children received a single dose of rectal artesunate (10 mg/kg) followed 12 hours later by intravenous artesunate (2.4 mg/kg) or the reverse order. All children also received standard doses of intravenous quinine. Artesunate and dihydroartemisinin were measured at eleven fixed intervals, following 0- and 12-hour drug administrations. Clinical, laboratory and parasitological parameters were measured.